#451 Christian Angermayer on Investing in Innovation

— Longevity as an investable thesis: Christian views aging as a disease rather than natural inevitability, focusing capital on therapies to extend healthy human lifespan significantly beyond current norms.

— Psychedelics for mental health: After personal experience with psilocybin, Christian founded Compass (first for-profit psychedelic company) and ATAI Life Sciences as a platform backing 12+ clinical-stage psychedelic drug candidates for depression, addiction, and PTSD.

— Biotech as best-performing asset class: 50% of Christian's portfolio is in biotech, driven by exponential cost reductions in sequencing and therapy development, plus shifting political priorities toward voter health.

— Mental health as underestimated crisis: Hundreds of millions suffer from depression and addiction; Christian emphasizes medical-supervised psychedelic therapy with trained guides rather than recreational use.

— Bitcoin as fiat hedge: Christian expects decade-long currency devaluation cycle from structural money-printing addiction; Bitcoin's integrity makes it core hedge alongside tech, fintech, and biotech.

— Deep tech and brain-computer interfaces: Christian invests across space, AI, robotics, and neural prosthetics, betting that direct brain-to-computer communication will transform human capability within 10–15 years.

— Position for optionality in longevity: If you believe exponential biotech progress will extend lifespan by 20+ years within your lifetime, allocate capital to proven longevity therapies and companies rather than treating aging as inevitable.

— Diversify across contrarian innovation: Build a portfolio spanning biotech, Bitcoin, fintech, and deep tech to capture asymmetric gains as fringe ideas move mainstream; long time horizons compound innovation faster than short-term trading ever will.